Switzerland-based drugs company Roche will initially provide Aileron with $25m and up to $1.1bn in milestone payments if developments are successful.

Aileron Therapeutics, a US-based biotechnology company, has signed a development deal worth potentially more than $1.1bn from one of its healthcare strategic investors.

Switzerland-based drugs company Roche will initially provide Aileron with $25m in technology access fees and research and development support work to develop drug candidates against up to five undisclosed targets in oncology, virology, inflammation, metabolism and the central nervous system.

If all five target areas produce successful drugs, Aileron can receive up to $1.1bn plus royalties.

In…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?